Skip header and navigation

Refine By

53 records – page 1 of 6.

35 years of marine natural product research in Sweden: Cool molecules and models from cold waters.

https://arctichealth.org/en/permalink/ahliterature283493
Source
Prog Mol Subcell Biol. 2017;55:1-34
Publication Type
Article
Date
2017
Author
Lars Bohlin
Paco Cárdenas
Anders Backlund
Ulf Göransson
Source
Prog Mol Subcell Biol. 2017;55:1-34
Date
2017
Language
English
Publication Type
Article
Keywords
Animals
Aquatic Organisms - chemistry - genetics
Biological Products - chemistry - therapeutic use
Biomedical Research - trends
Cold Temperature
Marine Biology - trends
Oceans and Seas
Porifera - chemistry - genetics
Sweden
Technology, Pharmaceutical - trends
Abstract
Currents efforts in marine biodiscovery have essentially focused on temperate to tropical shallow water organisms. With more than 6000 species of marine plants and animals, the Kosterfjord area has the richest marine biodiversity in Swedish waters, but it remains understudied. The overall objective of our marine pharmacognosy research is to explore and reveal the pharmacological potential of organisms from this poorly explored region. More generally, we wish to understand aspects of structure-activity relationships of chemical interactions in cold-water marine environment (shallow and deep). Our strategy is based on ecologically guided search for compounds through studies of physiology and organism interactions coupled to identification of bioactive molecules guided by especially in vivo assays. The research programme originated in the beginning of the 1980s with a broad screening of Swedish marine organisms using both in vitro and in vivo assays, resulting in isolation and identification of several different bioactive molecules. Two congenerous cyclopeptides, i.e. barettin and 8,9-dihydrobarettin, were isolated from the deep-sea sponge Geodia barretti, and structurally elucidated, guided by their antifouling activity and their affinity to a selection of human serotonin receptors. To optimize the activity a number of analogues of barettin were synthezised and tested for antifouling activity. Within the EU project BlueGenics, two larger homologous peptides, barrettides A and B, were isolated from G. baretti. Also, metabolic fingerprinting combined with sponge systematics was used to further study deep-sea natural product diversity in the genus Geodia. Finally, the chemical property space model 'ChemGPS-NP' has been developed and used in our research group, enabling a more efficient use of obtained compounds and exploration of possible biological activities and targets. Another approach is the broad application of phylogenetic frameworks, which can be used in prediction of where-in which organisms-to search for novel molecules or better sources of known molecules in marine organisms. In a further perspective, the deeper understanding of evolution and development of life on Earth can also provide answers to why marine organisms produce specific molecules.
PubMed ID
28238034 View in PubMed
Less detail
Source
Farm Zh. 1969;24(3):60-1
Publication Type
Article
Date
1969
Author
V I Levchenko
S A Nosovits'ka
Source
Farm Zh. 1969;24(3):60-1
Date
1969
Language
Ukrainian
Publication Type
Article
Keywords
Aminopyrine
Child
Dosage Forms
Humans
Pediatrics
Technology, Pharmaceutical
PubMed ID
5820733 View in PubMed
Less detail

Apomorphine to Uprima: the development of a practical erectogenic drug: a personal perspective.

https://arctichealth.org/en/permalink/ahliterature193900
Source
Int J Impot Res. 2001 Aug;13 Suppl 3:S29-34
Publication Type
Article
Date
Aug-2001
Author
A. Morales
Author Affiliation
Department of Urology Queen's University, Kingston, Canada. moralesa@post.queensu.ca
Source
Int J Impot Res. 2001 Aug;13 Suppl 3:S29-34
Date
Aug-2001
Language
English
Publication Type
Article
Keywords
Administration, Oral
Animals
Apomorphine - administration & dosage - history - therapeutic use
Canada
Clinical Trials, Phase IV as Topic
Dopamine Agonists - administration & dosage - history - therapeutic use
Drug Approval
Erectile Dysfunction - drug therapy - history
History, 19th Century
History, 20th Century
Humans
Male
Penile Erection - drug effects
Technology, Pharmaceutical - history
Abstract
The development process for apomorphine SL as an effective treatment for patients with erectile dysfunction has been somewhat unusual. As often is the case, much of the impetus for the basic research originated in academia. However, somewhat unusually, the impetus for early stage clinical research also lay in the hands of the academics. This article represents a historical perspective from one of those involved throughout.
PubMed ID
11477489 View in PubMed
Less detail

[Brief characteristic of comprehensive project "development of technology of differential proteomics and its application to development of new anticancer drugs"].

https://arctichealth.org/en/permalink/ahliterature167692
Source
Mol Gen Mikrobiol Virusol. 2006;(3):3-10
Publication Type
Article
Date
2006

Cell culture–derived influenza vaccines: has their time come?

https://arctichealth.org/en/permalink/ahliterature140533
Source
Clin Infect Dis. 2010 Nov 1;51(9):1005-6
Publication Type
Article
Date
Nov-1-2010

[Composition and preparation of fatty emulsions for parenteral feeding]

https://arctichealth.org/en/permalink/ahliterature8951
Source
Farm Zh. 1970;25(5):3-11
Publication Type
Article
Date
1970

Cost savings from intravenous immunoglobulin manufactured from chromotography/caprylate (IGIV-C) in persons with primary humoral immunodeficiency disorder.

https://arctichealth.org/en/permalink/ahliterature173401
Source
Value Health. 2005 Jul-Aug;8(4):488-94
Publication Type
Article
Author
Parthiv J Mahadevia
John Strell
Dan Kunaprayoon
Erwin Gelfand
Author Affiliation
MEDTAP International Inc., Bethesda, MD 20814, USA.
Source
Value Health. 2005 Jul-Aug;8(4):488-94
Language
English
Publication Type
Article
Keywords
Adult
Canada
Caprylates
Chromatography
Cost Savings
Cost of Illness
Drug Contamination - economics - prevention & control
Female
Humans
Immunoglobulins, Intravenous - adverse effects - economics
Immunologic Deficiency Syndromes - drug therapy - economics
Likelihood Functions
Male
Models, Econometric
Multivariate Analysis
Randomized Controlled Trials as Topic
Respiratory Tract Infections - economics - prevention & control
Retrospective Studies
Technology, Pharmaceutical - economics
United States
Abstract
Human intravenous immunoglobulin manufactured with chromatography and caprylate methods (IGIV-C, 10%) was associated with a reduction in validated infections (pneumonia and sinusitis) compared with treatment with a licensed immunoglobulin product manufactured using standard solvent-detergent methods (IGIV-SD, 10%) in participants with primary humoral immunodeficiency disorder (PIDD). Our objective was to determine the cost-consequences of using IGIV-C instead of IGIV-SD.
Economic analysis of a double-blind, randomized, clinical trial was used. Participants were randomly assigned to IGIV-C (N = 87) or IGIV-SD (N = 85) and monitored for the development of validated infections over the course of 9 months. Consumed resources were enumerated including cost of physician and emergency room visits, medications (prescription and over-the-counter), work productivity losses, and hospitalizations. Resource data was obtained from case report forms, patient diaries and the trial medication database. Because the amount of IGIV-SD used exceeded that of IGIV-C (nonstatistically significant difference) and the products are equivalently priced, we conservatively excluded investigational product acquisition cost to avoid artificially biasing incremental cost differences. We used a societal perspective with indirect costs, measured in 2003 US dollars. Pricing of both IGIV products is anticipated to be equivalent.
In a multivariate analysis, annual mean per participant costs were significantly lower between those receiving IGIV-C compared with IGIV-SD for prescription medications [-US 302 dollars, 95% confidence interval (CI) -US 598 dollars to -US 6 dollars], hospitalization (-US 1454 dollars, 95% CI -US 1828 dollars to -US 1080 dollars) and total costs (-US 1304 dollars, 95% CI -US 1867 dollars to -US 742 dollars). Costs associated with lost work productivity and physician visits were similar in both groups (P > 0.10). In sensitivity analyses, varying costs of concomitant medications, hospitalization and outpatient care, did not significantly change our results.
IGIV-C is cost-saving compared with IGIV-SD among persons with PIDD.
PubMed ID
16091026 View in PubMed
Less detail

[Development of an optimal enteric-soluble film-forming composite based on acetylphthalylcellulose for coating tablets in a fluidized bed]

https://arctichealth.org/en/permalink/ahliterature8886
Source
Farm Zh. 1975 Mar-Apr;(2):47-51
Publication Type
Article

[Development of the optimal film-forming composition based on ethylcellulose for the protective coating of tablets on a fluidized bed]

https://arctichealth.org/en/permalink/ahliterature13216
Source
Farm Zh. 1976 Mar-Apr;(2):65-8
Publication Type
Article

Development, use and evaluation of drugs: the dominating technology in the health care system.

https://arctichealth.org/en/permalink/ahliterature236048
Source
Soc Sci Med. 1987;25(1):65-73
Publication Type
Article
Date
1987
Author
E H Hansen
L. Launsø
Source
Soc Sci Med. 1987;25(1):65-73
Date
1987
Language
English
Publication Type
Article
Keywords
Clinical Trials as Topic
Delivery of Health Care
Denmark
Drug Industry
Drug Utilization
Health Policy
Humans
Physicians, Family
Placebos
Safety
Technology, Pharmaceutical
Therapeutics
Abstract
The article presents various perspectives of drug technology and health care policy in Denmark. Drugs dominate as the most widely used treatment technology in the health care system and the use of drugs is steadily increasing. The pharmaceutical industry's development of drugs is based on an economic estimate of developments, expenditures, marketing costs and the anticipated share of the market. Controlled clinical trials have become the main form of documentation required by the health authorities. This method is insufficient to evaluate the (side) effects of the drugs when in actual use. Drugs fit perfectly the technical perception of disease, a perception which prevails in the pharmaceutical industry, medical science and in the treatment of disease. This perception believes that a disease is due to an attack or dysfunction in the biological-mechanical conditions of the individual. Drugs offer a standard solution to health problems independent of the individuals' social life. Thus drugs become a tool which function in agreement with the disintegrated and achievement-orientated approach to disease as it is organized today. In general the statements in this article are not limited to special Danish circumstances but are valid for other countries as well [1, 2]. (Norris R. Pills, Pesticides & Profits. North River Press, 1982; Braithwaite J. Corporate Crime in the Pharmaceutical Industry. Routledge & Kegan Paul, London, 1984) The empirical data in this article derive from Denmark, however.
PubMed ID
3303354 View in PubMed
Less detail

53 records – page 1 of 6.